Ved et virologisk svigt i PREZISTA/ ritonavir- gruppen blev der identificeret 1 NRTI RAM i udvikling ved position 184, der var forbundet med nedsat følsomhed over for emtricitabin, som var inkluderet i baggrundsregimet.
In 1 virologic failure of the PREZISTA/ritonavir group, 1 developing NRTI RAM at position 184 was identified, which was associated with a decreased susceptibility to emtricitabine included in the background regimen.